Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- 4 Medical Devices Recommended for Approval
October 26, 2009
- NHI Price Revision Rate, Policy to Be Proposed by Panel under Health Minister
October 26, 2009
- NEW PRODUCTS／Yakuban Tape 60 mg to Be Launched in December
October 26, 2009
- JMA Demands Increases in Medical Fees
October 26, 2009
- 32nd JSH Annual Scientific Meeting
October 26, 2009
- Forum Attendants Express Concern about Rising Dispensing Fees
October 26, 2009
- Findings from Evista's 3-Year PMS Reported
October 26, 2009
- No Mention Made on Development of Drugs at Korosho Policy Conference
October 26, 2009
- Blood Sugar Control Improved in Diabetes Patients Switching to Liraglutide: Novo Nordisk
October 26, 2009
- New Administration Route Approved for Temodal
October 26, 2009
- Incretin Therapy Suitable for Japanese Patients with Diabetes: Dr Seino
October 26, 2009
- REGULATORY NEWS IN BRIEF
October 26, 2009
- Biogen Idec Japan Aims at 50% Share in Market for IFN-b
October 26, 2009
- Shionogi Allies with UK Universities, Bioventures for Drug Discovery
October 26, 2009
- Rasilez May Become Blockbuster: T. Rosenberg, Novartis
October 26, 2009
- Life Science Degrades to 2nd Place in Priority Science and Technology Ranking
October 26, 2009
- Datamonitor Predicts that Acquisition of Solvay Will Have Positive Effects on Abbott
October 26, 2009
- R＆D NEWS IN BRIEF
October 26, 2009
- Additional Safety Information to Be Provided on Obescare
October 19, 2009
- GSK, Novartis Contract with Korosho to Supply Flu Vaccines
October 19, 2009
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…